HIV p17 Gag 77-85

HIV p17 Gag 77-85 is a synthetic peptide fragment derived from the HIV-1 Gag protein, specifically encompassing amino acid residues 77 to 85 of the p17 matrix region. As a well-characterized epitope, this peptide holds significant relevance in virology and immunology research, particularly in studies focused on viral assembly, immune recognition, and T-cell epitope mapping. Its sequence specificity and defined structure make it a valuable molecular tool for investigating the biochemical and immunological properties of the HIV Gag protein, as well as for advancing the understanding of host-pathogen interactions at the peptide level.

Epitope mapping: The peptide is widely utilized in epitope mapping studies to identify and characterize T-cell responses against HIV-1. Researchers employ it to delineate the precise regions of the Gag protein recognized by cytotoxic T lymphocytes, thereby providing insight into immune surveillance mechanisms and antigen presentation pathways. This application is pivotal for elucidating the molecular determinants of immune recognition and for informing the design of immunological assays and experimental vaccines.

Immunoassay development: HIV p17 Gag 77-85 serves as a critical reagent in the development and optimization of immunoassays, including ELISPOT and intracellular cytokine staining protocols. By acting as a defined antigenic target, it enables the quantification and functional assessment of HIV-specific T-cell populations in experimental systems. Such assays are instrumental in monitoring immune competence, evaluating vaccine-induced responses, and validating immunotherapeutic strategies in preclinical research settings.

Peptide-MHC binding studies: The defined sequence of this peptide fragment makes it a valuable substrate for in vitro binding assays with major histocompatibility complex (MHC) molecules. Researchers leverage it to assess the affinity and stability of peptide-MHC complexes, which is fundamental for understanding antigen processing and presentation. These studies contribute to the broader field of immunopeptidomics and facilitate the rational design of peptide-based immunogens.

Antigen processing research: As a representative segment of the HIV-1 Gag protein, the peptide is frequently used to investigate the intracellular pathways involved in antigen processing. Experimental systems incorporating this fragment allow for the dissection of proteasomal degradation, peptide transport, and MHC class I loading mechanisms. Insights gained from such research support the development of strategies to manipulate antigen presentation for immunological research and vaccine development.

Peptide functional studies: The biochemical properties of HIV p17 Gag 77-85 also render it suitable for peptide functional studies, where it can be used to probe protein-protein interactions, structural dynamics, or post-translational modifications associated with the Gag matrix region. Utilizing synthetic peptides in this context enables precise control over experimental variables and supports mechanistic investigations into the role of specific protein domains in viral assembly and replication. Through these diverse applications, the peptide advances both fundamental virology research and translational studies in the field of HIV biology.

1. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

2. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

3. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

4. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation

5. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency